Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**VL#FIA3-30** is an investigational topical fixed-dose vasodilator combination developed by VasoLead for erectile dysfunction. Published reports describing this exact product identify its active ingredients as moxisylyte and isosorbide dinitrate, delivered with a tunica-penetrable topical delivery system for penile application. Moxisylyte blocks alpha-1 adrenergic receptor-mediated vasoconstriction, while isosorbide dinitrate serves as a nitric-oxide donor that promotes cyclic GMP-mediated smooth-muscle relaxation and penile engorgement. The product was evaluated in a Phase 1/2 study in men with erectile dysfunction. ([academic.oup.com](https://academic.oup.com/jsm/article-abstract/14/Supplement_4a/e179/6994869))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VL#FIA3-30.